康艾注射液联合肝动脉化疗栓塞术治疗肝癌34例临床观察

Clinical observation of Kang'ai-injection with TACE in 34 patients with hepatocellular carcinoma(HC)

目的探讨康艾注射液联合肝动脉化疗栓塞术治疗肝癌的临床疗效。方法70例患者随机分为两组,观察组34例与对照组36例均采用相同的肝动脉化疗栓塞术治疗,观察组联合康艾注射液治疗。结果观察组与对照组近期疗效RR分别为47.1%和44.4%,无显著性差异,P>0.05;观察组KPS改善率44.1%,明显高于对照组16.7%,P<0.05;观察组白细胞减少率47.05%,明显低于对照组66.67%,P<0.05;观察组SGPT升高异常率44.12%,明显低于对照组66.67%,P<0.05;观察组胆红素升高异常率26.47%,明显低于对照组52.78%,P<0.01;观察组在治疗前后比较,NK细胞活性升高,P<0.05。结论康艾注射液联合肝动脉化疗栓塞术治疗肝癌可改善生活质量,减轻毒副反应,提高NK细胞的免疫活性。

Objective To observe the efficacy of treating HC with Kang＇ai-injection with TACE. Methods All of 70 patients with HC divided into the observation group of 34 and the control group of 36 received TACE, and those in the observation group also received Kang＇ai-injection. Results Comparing the observation group with the other, response rate （RR） was 47.1% and 44.4%, respectively （P〉0.05）, with KPS improving rate 44.1% vs 16.7%（P〈0.05）, neutropenia 47.05% vs 66.67%（P〈0.05）, abnormal SGPT 44.12% vs 66.67（P〈0.05）,abnormal bilirubin 26.47% vs 52.78%（P〈0.01）, showing no better RR but the others much better. The levels of NK cells of the observation group increased after the treatment （P〈0.05）. Conclusions When treating patients with HC, Kang＇ai-injection with TACE could improve life quality, lessen toxicity and increase the levels of NK cells.